Announcements Trials
Browse Landscape

Phase

Phase 3 17Phase 4 14Phase NA 8Phase 2 5Phase 1/2 3Phase EARLY_PHASE1 2Phase 2/3 2Phase 1 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 1Stomach Neoplasms 1Pancreatic Neoplasms 1Liver Neoplasms 1Hemorrhage 1Colonic Neoplasms 1

Interventions

Cisplatin 98Gemcitabine 66Paclitaxel 62Carboplatin 60Fluorouracil 59Docetaxel 59Capecitabine 59Oxaliplatin 56Cyclophosphamide 54Radiotherapy 50Drug Therapy 46Bevacizumab 38pembrolizumab 35Dexamethasone 33Magnetic Resonance Spectroscopy 32Leucovorin 32Doxorubicin 31Cytarabine 27Etoposide 26Pemetrexed 25Nivolumab 24Methotrexate 24Radiation 20Vincristine 18venetoclax 17apatinib 17Rituximab 17Prednisone 17Letrozole 17Irinotecan 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Interventional × Tranexamic Acid × Clear all
NCT01869413 2022-10-04

TACT

Ottawa Hospital Research Institute

Phase 2/3 Completed
354 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT01655641 2012-10-16

TMGS

Tribhuvan University Teaching Hospital, Institute Of Medicine.

Phase 2/3 Unknown
118 enrolled
Gastrointestinal

Colonic Neoplasms, Hemorrhage, Liver Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡